Thrombin Generation Profile Using ST-Genesia after PEG-asparaginase in Pediatric Patients with Acute Lymphoblastic Leukemia
- 29 April 2024
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 124 (10) , 973-985
Abstract
Background Venous thromboembolism (VTE) etiology in children with acute lymphoblastic leukemia (ALL) is multifactorial. The use of global assays of hemostasis as a thrombin generation test (TGT) is useful to individualize VTE risk in adult patients. This prospective cohort study aimed to evaluate the usefulness of an automated TGT to evaluate VTE risk during ALL treatment in children. Methods TGT (automated analyzer ST Genesia; ThromboScreen) and pro- and anticoagulant plasma proteins were analyzed during ALL treatment in pediatric patients following LAL-SEHOP-PETHEMA-2013 guidelines. Results were compared with a series of pediatric normal controls and evaluated according to pegylated asparaginase PEG-ASP administration and to VTE risk factors. Results The study included 67 patients: males n = 35, B-ALL (n = 60). None had a VTE during the evaluated period. Compared to healthy controls, the normalized endogenous thrombin potential (N-ETP) ratio in patients was higher and ETP inhibition (ETP-inh) was lower, especially after PEG-ASP administration. Plasmatic protein C and protein S levels decreased after PEG-ASP administration, but antithrombin mean level did not. A bivariant analysis showed that ETP-inh was lower in patients >10 years old (p = 0.05) and in those with non-O blood type (p = 0.005). A linear mixed model also showed a higher TGT prothrombotic profile in patients with inherited thrombophilia. Conclusion TGT could be a biomarker of a high VTE risk in ALL pediatric patients. Non-O blood group and inherited thrombophilia were associated with a significantly higher thrombotic profile, and an increased profile was also observed after administration of PEG-ASP.Keywords
Funding Information
- Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España
- Instituto de Salud Carlos III (PI17/00356)
This publication has 44 references indexed in Scilit:
- Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana‐Farber Cancer Institute ALL Consortium trial 05‐001Pediatric Blood & Cancer, 2022
- Markers of hypercoagulability in children with newly diagnosed acute lymphoblastic leukemiaPediatric Blood & Cancer, 2021
- Lower incidence of clinical allergy with PEG‐asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG‐ASP in pediatric patients with acute lymphoblastic leukemiaHematological Oncology, 2021
- Thrombotic potential during pediatric acute lymphoblastic leukemia induction: Role of cell‐free DNAResearch and Practice in Thrombosis and Haemostasis, 2021
- Thrombosis is associated with worse survival in children with acute lymphoblastic leukemia: A report from CYP‐CAmerican Journal of Hematology, 2021
- Disordered hemostasis associated with severely depressed fibrinolysis demonstrated using a simultaneous thrombin and plasmin generation assay during L‐asparaginase induction therapy in pediatric acute lymphoblastic leukemiaPediatric Blood & Cancer, 2019
- Venous thromboembolism in a large cohort of children with acute lymphoblastic leukemia: Risk factors and effect on prognosisResearch and Practice in Thrombosis and Haemostasis, 2019
- Impact of baseline clinical and laboratory features on the risk of thrombosis in children with acute lymphoblastic leukemia: A prospective evaluationPediatric Blood & Cancer, 2018
- Different profile of thrombin generation in children with acute lymphoblastic leukaemia treated with native or pegylated asparaginase: A cohort studyPediatric Blood & Cancer, 2016
- Prospective study of hemostatic alterations in children with acute lymphoblastic leukemiaAmerican Journal of Hematology, 2010